血管生成
代谢途径
生物
萌芽血管生成
细胞生物学
信号转导
内皮干细胞
疾病
细胞代谢
电池类型
癌细胞
癌症研究
神经科学
细胞
新陈代谢
新生血管
癌症
医学
生物化学
病理
遗传学
体外
作者
Xuri Li,Xiaodong Sun,Peter Carmeliet
出处
期刊:Cell Metabolism
[Cell Press]
日期:2019-09-01
卷期号:30 (3): 414-433
被引量:336
标识
DOI:10.1016/j.cmet.2019.08.011
摘要
In 2009, it was postulated that endothelial cells (ECs) would only be able to execute the orders of growth factors if these cells would accordingly adapt their metabolism. Ten years later, it has become clear that ECs, often differently from other cell types, rely on distinct metabolic pathways to survive and form new blood vessels; that manipulation of EC metabolic pathways alone (even without changing angiogenic signaling) suffices to alter vessel sprouting; and that perturbations of these metabolic pathways can underlie excess formation of new blood vessels (angiogenesis) in cancer and ocular diseases. Initial proof of evidence has been provided that targeting (normalizing) these metabolic perturbations in diseased ECs and delivery of metabolites deserve increasing attention as novel therapeutic approaches for inhibiting or stimulating vessel growth in multiple disorders. In 2009, it was postulated that endothelial cells (ECs) would only be able to execute the orders of growth factors if these cells would accordingly adapt their metabolism. Ten years later, it has become clear that ECs, often differently from other cell types, rely on distinct metabolic pathways to survive and form new blood vessels; that manipulation of EC metabolic pathways alone (even without changing angiogenic signaling) suffices to alter vessel sprouting; and that perturbations of these metabolic pathways can underlie excess formation of new blood vessels (angiogenesis) in cancer and ocular diseases. Initial proof of evidence has been provided that targeting (normalizing) these metabolic perturbations in diseased ECs and delivery of metabolites deserve increasing attention as novel therapeutic approaches for inhibiting or stimulating vessel growth in multiple disorders.
科研通智能强力驱动
Strongly Powered by AbleSci AI